Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported R&D Expense of $254.9 thousand for fiscal year 2025.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $254.9K | -64.9% |
| 2024 | $726.2K | -19.1% |
| 2023 | $898.1K | -33.4% |
| 2022 | $1.35M | -22.3% |
| 2021 | $1.74M | +41.9% |
| 2020 | $1.22M | +49.1% |
| 2019 | $820.9K | +1916.8% |
| 2018 | $40.7K | -91.3% |
| 2017 | $467.3K | -46.3% |
| 2016 | $870.0K | -58.4% |
| 2015 | $2.09M | +87.1% |
| 2014 | $1.12M | +27.1% |
| 2013 | $879.9K | -13.1% |
| 2012 | $1.01M | -24.2% |
| 2011 | $1.33M | +199.6% |
| 2010 | $445.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.7K | -86.0% | -16.4% |
| June 30, 2025 | $60.6K | -71.2% | -33.7% |
| March 31, 2025 | $91.5K | -23.2% | -74.7% |
| September 30, 2024 | $361.6K | +173.0% | +71.6% |
| June 30, 2024 | $210.7K | -50.7% | +77.0% |
| March 31, 2024 | $119.1K | -37.0% | -10.1% |
| September 30, 2023 | $132.5K | -51.4% | -69.0% |
| June 30, 2023 | $427.5K | +159.4% | +126.1% |
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -64.9% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s r&d expense has declined by 42.8% (from $445.5 thousand to $254.9 thousand).
- The most recent figure is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: